D2R agonists can provoke dyskinesia in clinical stages of dopamine deficiency [1], [6]–[7] and inhibition of D1R signaling prevented dyskinesia in hemiparkinsonian rats [8]. Here, DRD1 is linked to drug-induced dyskinesia.